To benefit from new cancer drugs, reform the regulatory regime
HERE is a link to a Globe and Mail Commentary that David Stewart and I wrote.
It calls for reforms to improve the efficiency and cost-effectiveness of regulation overseeing clinical research on new therapy approaches for lethal diseases. Although the comment focuses on cancer, the same arguments apply to other lethal diseases such as muscular dystrophy, amyotrophic lateral sclerosis (ALS), Huntington disease and others.
The proposed reforms could help cut health care costs while at the same time greatly speeding approval of new treatments that could save lives and relieve suffering. We believe that Canada could lead the world in these very important reforms.
Posted by John-Peter Bradford, Range Advisors
Our passion is to support business owners in pursuit of their dreams.
We believe that for professional advice to be truly valuable to medium, small and entrepreneurial businesses, the adviser’s professional skills must be world-class, the adviser must participate in the effective execution of the solution and the advice must be affordable by the business. With this, these businesses can overcome all challenges.